Evaluation of MiR-1908-3p as a novel serum biomarker for breast cancer and analysis its oncogenic function and target genes

Table 1 Clinicopathological variables and the expression of miR-1908-3p in the breast cancer tissues

Variable	Number	Mean of miR-1908-3p expression	p value
Age			< 0.05
≤ 40	25 (50%)	14.89
> 40	25 (50%)	5.54
metastasis			0.25
Negative	21 (42%)	6.83
Positive	29 (58%)	12.66
Grade			0.54
1	3 (6%)	12.49
2	21 (42%)	6.97
3	26 (52%)	12.57
TNM			0.66
I/II	36 (72%)	9.53
III/IV	14 (28%)	11.95
Tumor size			0.84
≤ 2	20 (40%)	8.39
> 2,≤5	28 (56%)	11.33
> 5	2 (4%)	12.68
ER statue			0.41
Negative	16 (32%)	7.24
Positive	34 (68%)	11.61
PR statue			0.3
Negative	19 (38%)	6.36
Positive	31 (62%)	12.22
HER-2			< 0.01
Negative	35 (70%)	5.59
Positive	15 (30%)	20.98
Molecular Subtype			0.65
luminal	34 (68%)	11.61
her-2+	8 (16%)	9.14
Triple-negative	8 (16%)	5.34

Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2

ISSN: 1471-2407